Current Management of Primary Central Nervous System Lymphoma

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3, 2010, Pages 666-678

  Schultz, Christopher J ^a   Bovi, Joseph ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEMS; FRACTIONATION SCHEDULES; HIGH DOSE; HIGH RATE; HIGH RESPONSE; MULTI-FACTOR; MULTIFOCAL; NEUROTOXICITY; PRE-TREATMENT; SPINAL CORDS; SUBARACHNOID SPACES; TOTAL DOSE; TUMOR CONTROL; WHOLE BRAIN RADIOTHERAPY; WHOLE-BRAIN RADIATION;

ONCOLOGY; TUMORS;

CHEMOTHERAPY;

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; GANCICLOVIR; HYDROCORTISONE; IFOSFAMIDE; LOMUSTINE; MANNITOL; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RELAPSE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; DRUG EXCRETION; DRUG MEGADOSE; ENCEPHALOMALACIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; LEUKOENCEPHALOPATHY; LUMBAR PUNCTURE; MENTAL DISEASE; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECURRENT CANCER; REVIEW; SIDE EFFECT; SUBARACHNOID SPACE; SURVIVAL TIME; TREATMENT PLANNING; TREATMENT RESPONSE; WHITE MATTER; WHOLE BODY CT;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DIAGNOSTIC IMAGING; HUMANS; IMMUNOCOMPETENCE; LYMPHOMA; LYMPHOMA, AIDS-RELATED; PROGNOSIS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 76049085618     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.10.011     Document Type: Review

References (72)

1. U.S. cancer statistics working group. united states cancer statistics: 1999-2004 incidence and mortality web-based report. atlanta: U.S. department of health and human services, centers for disease control and prevention and national cancer institute [homepage on the Internet].. 2007 [cited 1/22/2008]. Available from: http://apps.nccd.cdc.gov/uscs/Table.aspx?Group=TableAll&Year=2004&Display=n. Last accessed December 12, 2009.
2. CBTRUS. statistical report:Primary brain tumors in the united states, 1998-2002 (2005), Published by the Central Brain Tumor Registry of the United States, Hinsdale, IL
3. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 43 3 (1999 Jul) 199-201
4. Bataille B., Delwail V., Menet E., Vandermarco P., Ingrand I., Wager M., et al. Primary intracerebral malignant lymphoma: Report of 248 cases. J Neurosurg 92 (2000) 261-266
5. Partap S., and Spence A.M. Spontaneously relapsing and remitting primary CNS lymphoma in an immunocompetent 45-year-old man. J Neurooncol 80 3 (2006 Dec) 305-307
6. Shenkier T.N. Unusual variants of primary central nervous system lymphoma. Hematology - Oncology Clinics of North America (2005) vi; Aug;19(4):651-64
7. Abrey L.E., Batchelor T.T., Ferreri A.J., Gospodarowicz M., Pulczynski E.J., Zucca E., et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. Journal of Clinical Oncology 23 22 (2005 Aug 1) 5034-5043
8. Correa D., Maron L., Harder H., Klein M., Armstrong C., Calabrese P., et al. Cognitive functions in primary central nervous system lymphoma: Literature review and assessment guidelines. Ann Oncol 18 7 (2007 July 1) 1145-1151
9. Ekstein D., Ben-Yehuda D., Slyusarevsky E., Lossos A., Linetsky E., and Siegal T. CSF analysis of IgH gene rearrangement in CNS lymphoma: Relationship to the disease course. J Neurol Sci 247 1 (2006 Aug 15) 39-46
10. Cinque P., Brytting M., Vago L., Castagna A., Parravicini C., Zanchetta N., et al. Epstein-barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet 342 8868 (1993 Aug 14) 398-401
11. Yu H., Xie Y., and Wang G. [The clinical features and prognostic factors of 22 patients with primary central nervous system lymphoma]. Chung-Hua Nei Ko Tsa Chih Chinese Journal of Internal Medicine 40 5 (2001 May) 325-328
12. De Luca A., Antinori A., Cingolani A., Larocca L.M., Linzalone A., Ammassari A., et al. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Haematol 90 4 (1995 Aug) 844-849
13. Coulon A., Lafitte F., Hoang-Xuan K., Martin-Duverneuil N., Mokhtari K., Blustajn J., et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol 12 2 (2002 Feb) 329-340
14. Thurnher M.M., Rieger A., Kleibl-Popov C., Settinek U., Henk C., Haberler C., et al. Primary central nervous system lymphoma in AIDS: A wider spectrum of CT and MRI findings. Neuroradiology 43 1 (2001 Jan) 29-35
15. Kuker W., Nagele T., Korfel A., Heckl S., Thiel E., Bamberg M., et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol 72 2 (2005 Apr) 169-177
16. Raizer J.J., Koutcher J.A., Abrey L.E., Panageas K.S., DeAngelis L.M., Lis E., et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neurooncol 71 2 (2005 Jan) 173-180
17. Villringer K., Jager H., Dichgans M., Ziegler S., Poppinger J., Herz M., et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 19 4 (1995 Jul-Aug) 532-536
18. Mohile N.A., DeAngelis L.M., and Abrey L.E. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro-oncol 10 2 (2008 April 1) 223-228
19. Palmedo H., Urbach H., Bender H., Schlegel U., Schmidt-Wolf I.G., Matthies A., et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: Correlation with MRI and clinical follow-up. European Journal of Nuclear Medicine & Molecular Imaging 33 2 (2006 Feb) 164-168
20. Paulus W. Classification, pathogenesis. and molecular pathology of primary CNS lymphomas. J Neurooncol (1999) [cited 1/2/2008];43(3):203-8
21. DeAngelis L.M., Wong E., Rosenblum M., and Furneaux H. Epstein-barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma. Cancer 70 6 (1992 Sep 15) 1607-1611
22. Rao C.R., Jain K., Bhatia K., Laksmaiah K.C., and Shankar S.K. Association of primary central nervous system lymphomas with the epstein-barr virus. Neurol India 51 2 (2003 Jun) 237-240
23. Nelson D.F., Martz K.L., Bonner H., Neson J.S., Newall J., Kerman H.D., et al. Non-hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23 (1992) 9-17
24. O'Neill B.P., O'Fallon J.R., Earle J.D., Colgan J.P., Brown L.D., and Krigel R.L. Primary central nervous system non-hodgkin's lymphoma: Survival advantages with combined initial therapy?. Int J Radiat Oncol Biol Phys 33 3 (1995 10/15) 663-673
25. Schultz C.J., Scott C., Sherman W., Donahue B., Fields J., Murray K., et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: Initial report of radiation therapy -oncology group protocol 88-06. J Clin Oncol 14 (1996) 556-564
26. DeAngelis L.M., Seiferheld W., Schold S.C., Fisher B., and Schultz C.J. Radiation Therapy Oncology Group Study,93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation therapy oncology group study 93-10. Journal of Clinical Oncology 20 24 (2002 Dec 15) 4643-4648
27. Corry J., Smith J.G., Wirth A., Quong G., and Liew K.H. Primary central nervous system lymphoma: Age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 41 3 (1998 Jun 1) 615-620
28. Bessell E.M., Graus F., Lopez-Guillermo A., Lewis S.A., Villa S., Verger E., et al. Primary non-hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: Long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 59 2 (2004 6/1) 501-508
29. Ferreri A.J.M., Blay J., Reni M., Pasini F., Spina M., Ambrosetti A., et al. Prognostic scoring system for primary CNS lymphomas: The international extranodal lymphoma study group experience. J Clin Oncol 21 2 (2003 January 15) 266-272
30. Abrey L.E., Ben-Porat L., Panageas K.S., Yahalom J., Berkey B., Curran W., et al. Primary central nervous system lymphoma: The memorial sloan-kettering cancer center prognostic model. Journal of Clinical Oncology 24 36 (2006 Dec 20) 5711-5715
31. Larocca L.M., Capello D., Rinelli A., Nori S., Antinori A., Gloghini A., et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. Blood 92 3 (1998 Aug 1) 1011-1019
32. Braaten K.M., Betensky R.A., de Leval L., Okada Y., Hochberg F.H., Louis D.N., et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 9 3 (2003 March 1) 1063-1069
33. Murray K., Kun L., and Cox J. Primary malignant lymphoma of the central nervous system: Results of the treatment of 11 cases and review of the literature. J Neurosurg 65 (1986) 600-607
34. Corn B.W., Dolinskas C., Scott C., Donahue B., Schultz C., Nelson D.F., et al. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: A secondary analysis of RTOG studies 83-15 and 88-06. Int J Radiat Oncol Biol Phys 47 2 (2000 May 1) 299-303
35. DeAngelis L.M., Yahalom J., Thaler H.T., and Kher U. Combined modality therapy for primary CNS lymphoma. Journal of Clinical Oncology 10 4 (1992 Apr) 635-643
36. Fisher B., Seiferheld W., Schultz C., DeAngelis L., Nelson D., Schold S.C., et al. Secondary analysis of radiation therapy oncology group study (RTOG) 9310: An intergroup phase II combined modality treatment of primary central nervous system lymphoma. J Neurooncol 74 2 (2005 Sep) 201-205
37. Bessell E.M., Lopez-Guillermo A., Villa S., Verger E., Nomdedeu B., Petit J., et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: An analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. Journal of Clinical Oncology 20 1 (2002 Jan 1) 231-236
38. Shah G.D., Yahalom J., Correa D.D., Lai R.K., Raizer J.J., Schiff D., et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology 25 30 (2007 Oct 20) 4730-4735
39. Ott R.J., Brada M., and Flowers M.A. Measurements of blood-brain barrier permiability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 27 (1991) 1356-1361
40. Khan R.B., Shi W., Thaler H.T., DeAngelis L.M., and Abrey L.E. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol 58 2 (2002 Jun) 175-178
41. Neuwelt E., Goldman D., Dahlborg S., Crossen J., Ramsey F., Roman-Goldstein S., et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function. J Clin Oncol 9 9 (1991 September 1) 1580-1590
42. Montemurro M., Kiefer T., Schuler F., Al-Ali H.K., Wolf H.H., Herbst R., et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: Results of the multicenter ostdeutsche studiengruppe hamato-onkologie OSHO-53 phase II study. Annals of Oncology 18 4 (2007 Apr) 665-671
43. Colombat P., Lemevel A., Bertrand P., Delwail V., Rachieru P., Brion A., et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38 6 (2006 Sep) 417-420
44. Soussain C., Suzan F., Hoang-Xuan K., Cassoux N., Levy V., Azar N., et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of Clinical Oncology 19 3 (2001 Feb 1) 742-749
45. Enting R.H., Demopoulos A., DeAngelis L.M., and Abrey L.E. Salvage therapy for primary CNS lymphoma with a combination temozolamide and rituximab. Neurology 40 (2004) 1682-1688
46. Plotkin S.R., Betensky R.A., and Hochberg F. Treatment of relapsed central nervous system lymphoma with high dose methotrexate. Clin Cancer Res 10 (2004) 5643-5646
47. Herrlinger U., Brugger W., Bamberg M., Kuker W., Dichgans J., and Weller M. PCV salvage chemotherapy for for recurrent primary CNS lymphoma. Neurology 54 (2000) 1707-1708
48. Nguyen P., Chakravarti A., Finkelstein D., Hochberg F., Batchelor T.T., and Loeffler J. Results of whole brain radiation as salvage of methotrexate failurefor immunocompetent patients with primary CNS lymphoma. J Clin Oncol 23 (2005) 1507-1513
49. Voloschin A.D., Betensky R.A., Wen P.Y., Hochberg F., and Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 86 (2008) 211-215
50. Kasamon Y.L., and Ambinder R.F. AIDS-related primary central nervous system lymphoma. Hematology - Oncology Clinics of North America (2005) vi-vii; Aug;19(4):665-87
51. Ambinder R.F., Lee S., Curran W.J., Sparano J.A., Krigel R.L., McArthur J., et al. Phase II intergroup trial of sequential chemotherapy and radiationtherapy for AIDS-related primary central nervous system lymphoma. Cancer Therapy 1 (2003) 215-221
52. Hoffmann C., Tabrizian S., Wolf E., Eggers C., Stoehr A., Plettenberg A., et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15 16 (2001 Nov 9) 2119-2127
53. Pajonk F., and McBride W.H. Survival of AIDS patients with primary central nervous system lymphoma may be improved by the radiosensitizing effects of highly active antiretroviral therapy. AIDS 16 8 (2002 May 24) 1195-1196
54. Newell M.E., Hoy J.F., Cooper S.G., DeGraaff B., Grulich A.E., Bryant M., et al. Human immunodeficiency virus-related primary central nervous system lymphoma: Factors influencing survival in 111 patients. Cancer 100 12 (2004 Jun 15) 2627-2636
55. Raez L., Cabral L., Cai J., Landy H., Sfakianakis G., Byrne G.E., et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 15 8 (1999 05/20) 713-719
56. Aboulafia D.M. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clinical Infectious Diseases 34 12 (2002 Jun 15) 1660-1662
57. Bossolasco S., Falk K.I., Ponzoni M., Ceserani N., Crippa F., Lazzarin A., et al. Ganciclovir is associated with low or undetectable epstein-barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clinical Infectious Diseases 42 4 (2006 Feb 15) e21-e25
58. Abrey L.E., and Correa D.D. Treatment-related neurotoxicity. Hematology - Oncology Clinics of North America (2005) viii; Aug;19(4):729-38
59. Gavrilovic I.T., Hormigo A., Yahalom J., DeAngelis L.M., and Abrey L.E. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. Journal of Clinical Oncology 24 28 (2006 Oct 1) 4570-4574
60. Abrey L.E., Yahalom J., and DeAngelis L.M. Treatment for primary CNS lymphoma: The next step. Journal of Clinical Oncology 18 17 (2000 Sep) 3144-3150
61. Abrey L.E., DeAngelis L.M., and Yahalom J. Long-term survival in primary CNS lymphoma. Journal of Clinical Oncology 16 3 (1998 Mar) 859-863
62. Ferreri A.J., Abrey L.E., Blay J.Y., Borisch B., Hochman J., Neuwelt E.A., et al. Summary statement on primary central nervous system lymphomas from the eighth international conference on malignant lymphoma, lugano, switzerland, june 12 to 15, 2002. Journal of Clinical Oncology 21 12 (2003 Jun 15) 2407-2414
63. Poortmans P.M., Kluin-Nelemans H.C., Haaxma-Reiche H., Van't Veer M., Hansen M., Soubeyran P., et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organization for research and treatment of cancer lymphoma group phase II trial 20962. Journal of Clinical Oncology 21 24 (2003 Dec 15) 4483-4488
64. O'Brien P.C., Roos D.E., Pratt G., Liew K.H., Barton M.B., Poulsen M.G., et al. Combined-modality therapy for primary central nervous system lymphoma: Long-term data from a phase II multicenter study (trans-tasman radiation oncology group). Int J Radiat Oncol Biol Phys 64 2 (2006 Feb 1) 408-413
65. Blay J., Bouhour D., Carrie C., Bouffet E., Brunat-Mentigny M., Philip T., et al. The C5R protocol: A regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]. Blood 86 8 (1995 October 15) 2922-2929
66. Brada M., Hjiyiannakis D., Hines F., Traish D., and Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys. 3/15 40 5 (1998) 1157-1162
67. Pels H., Schmidt-Wolf I.G., Glasmacher A., Schulz H., Engert A., Diehl V., et al. Primary central nervous system lymphoma: Results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. Journal of Clinical Oncology 21 24 (2003 Dec 15) 4489-4495
68. Gerstner E.R., Carson K.A., Grossman S.A., and Batchelor T.T. Long term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70 5 (2008 January 29) 401-402
69. Batchelor T., Carson K., O'Neill A., Grossman S.A., Alavi J., New P., et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07. J Clin Oncol 21 (2003) 1044-1049
70. Hoang-Xuan K., Taillandier L., Chinot O., Soubeyran P., Bogdhan U., Hildebrand J., et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: A multicenter phase II study (26952) of the european organization for research and treatment of cancer brain tumor group. Journal of Clinical Oncology 21 14 (2003 Jul 15) 2726-2731
71. Sandor V., Stark-Vancs V., Pearson D., Nussenblat R., Whitcup S.M., Brouwers P., et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. Journal of Clinical Oncology 16 9 (1998 Sep) 3000-3006
72. Dahlborg S.A., Henner W.D., Crossen J.R., Tableman C.M., Petrillo A., Braziel R., et al. Non-AIDS primary CNS lymphoma: First example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am (1996 May-Jun) [cited 10/29/2008];2(3):166-174